In short, as I understand it, Zenith Epigenetics Ltd holds all the oncology indications, the lead compound being ZEN-3694. If ZCC sells its subsidiary Zenith Epigenetics Ltd., in my opinion, that needs to get the approval of the shareholders holding "ZHCLF" shares. Cash from the sale will flow onto ZCC. At that point, ZCC will hold the funds from the sale of Zenith Epigenetics +the Resverlogix Royalty Preferred Shares. What the company will do with the cash is anybody's guess.  Buy another business or pay them out to shareholders as dividends from the retained earnings. If it gets to this stage there is no revenue-generating enterprise left other than the company holding lots of cash. At this point, the company will be in no position to offer a new share issue. As RVXOT stated it becomes a holding company. !!!??? 

Koo